Recent 8-K filings for PTN
Highest-materiality recent filing
Palatin Technologies receives NYSE American delisting notice; intends to appeal
- NYSE Regulation determined to delist PTN for failure to comply with stockholders' equity requirements (Sections 1003(a)(i)-(iii)).
- Maximum 18-month compliance plan ended April 10, 2025; Company unable to demonstrate regained compliance.
-
Palatin closes $18.2M public offering, regains NYSE American listing compliance
Closed upsized public offering of 2,795,384 shares/pre-funded warrants and warrants at combined $6.50, gross proceeds $18.2M.
-
Palatin prices $15.8M public offering; NYSE American listing resumes Nov 12
Priced upsized public offering of 2.43M shares at $6.50/unit; gross proceeds ~$15.8M.
-
Palatin earns €5.5M milestone payment from Boehringer Ingelheim in retinal disease collaboration
Achieved research milestone in collaboration with Boehringer Ingelheim, triggering €5.5M ($6.5M) payment to Palatin.
-
Palatin begins OTCQB trading under PTNT after 1-for-50 reverse split; delisted from NYSE American
NYSE American suspended trading and initiated delisting on May 7, 2025, due to low stock price.
-
Palatin signs up to €280M collaboration with Boehringer for retinal disease therapies
€2M upfront, up to €18M near-term milestones, up to €260M in regulatory/commercial milestones plus tiered royalties.
-
Palatin Technologies to effect 1-for-50 reverse stock split on August 11, 2025
Reverse split effective after market on August 11; split-adjusted trading on OTCQB begins August 12.
-
Palatin Technologies announces 1-for-50 reverse stock split effective Aug 8, 2025
Reverse stock split at 1-for-50 ratio effective 5:00 p.m. ET on August 8, 2025.
-
Palatin shareholders approve reverse stock split (1:50-1:100) and increase shares for equity awards
Reverse stock split (1:50-1:100) approved; 12.4M for, 8.2M against. Board to set exact ratio.
-
NYSE American Panel affirms delisting of Palatin Technologies; stock trades on OTCQB
Panel unanimously affirmed delisting under Sections 1003(a) and 1003(f)(v) due to low selling price of common stock.
-
Palatin Technologies delisted from NYSE American; raises $340K in insider private placement
NYSE American commenced delisting proceedings; common stock suspended May 7, 2025. Now trades on OTCQB under PTNT.
-
Palatin Technologies delisted from NYSE American; reduced offering raises only $1.1M
NYSE American suspended trading and commenced delisting proceedings due to low stock price; shares transitioned to OTC Pink under 'PTNT'.
-
Palatin Technologies receives NYSE American delisting notice; intends to appeal
NYSE Regulation determined to delist PTN for failure to comply with stockholders' equity requirements (Sections 1003(a)(i)-(iii)).
-
Palatin reports positive Phase 2 topline results for UC drug PL8177 and obesity combo study
UC Phase 2: Clinical remission 33% PL8177 vs 0% placebo; clinical response 78% vs 33% (p<0.005) after 8 weeks.
-
Palatin Technologies announces $4.7M equity offering at $1.00/share, private warrants
Gross proceeds ~$4.7M from sale of 2.55M shares at $1.00/share and pre-funded warrants for 2.138M shares.
-
Palatin receives ~$3.4M from warrant exercise; issues new Series C/D warrants
Gross proceeds of ~$3.4M from exercise of 3,907,679 shares at amended price $0.875.
-
Net loss $7.8M ($0.39/share) vs $5.2M a year ago; cash $2.4M at Sep 30, plus $2.5M deferred payment from Vyleesi sale received Nov 2024.
-
NYSE American notified Palatin of non-compliance with Section 1003(a)(iii) requiring stockholders' equity of at least $6M after five consecutive years of losses.
-
Net loss for FY2024 $29.7M ($2.02 per share) vs $24.0M ($2.21) prior year; revenue declined as Vyleesi asset sold.
-
Palatin Technologies raises ~$6.1M via warrant inducement with institutional investor
Enters inducement letter; institutional investor exercises existing warrants for $6.1M gross proceeds.
-
Palatin Q3 net loss $8.4M; Phase 3 DED study meets pain endpoint, 7 of 11 secondary endpoints
Phase 3 MELODY-1 for PL9643 in dry eye disease met co-primary pain endpoint (P<0.025) and 7 of 11 secondary endpoints at 12 weeks; rapid onset at 2 weeks.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.70 · Most common event other_material